Unfractionated Heparin for Venous Thromboembolism Prophylaxis

Dosage and Scheduling

• The standard prophylactic dose of unfractionated heparin (UFH) is 5,000 IU administered subcutaneously every 8 hours in hospitalized patients. 1
• Administering UFH every 8 hours is more effective than every 12 hours for preventing venous thromboembolism (VTE) in hospitalized adults. 2
• The NCCN, ASCO, and ESMO guidelines recommend the 8‑hour regimen as the preferred prophylactic schedule despite a higher bleeding risk. 1

Duration of Prophylaxis

• In medically‑ill inpatients, UFH prophylaxis should be continued throughout the hospital stay until the patient regains full ambulation. 1
• Prophylaxis must be maintained as long as VTE risk factors persist (e.g., immobility, active cancer, recent surgery). 3

Population‑Specific Recommendations

Surgical Oncology Patients

• UFH 5,000 IU every 8 hours is equally effective and safe compared with low‑molecular‑weight heparin (LMWH) for VTE prevention after cancer surgery. 2

Patients with Severe Renal Impairment (CrCl < 30 mL/min)

• UFH is the anticoagulant of choice because it is primarily cleared hepatically, making it suitable for patients with markedly reduced renal function. 4
• LMWH is contraindicated or requires dose adjustment with anti‑Xa monitoring in this setting. 1
• Fondaparinux is contraindicated when creatinine clearance is below 30 mL/min. 4

Critically Ill Patients with Sepsis

• The Surviving Sepsis Campaign recommends pharmacologic VTE prophylaxis with UFH or LMWH in patients with severe sepsis. 5
• LMWH is preferred over UFH to limit staff exposure and conserve personal protective equipment. 6
• In septic patients with CrCl < 30 mL/min, UFH 5,000 IU given two to three times daily is an acceptable alternative. 6

Hospitalized Non‑Critical COVID‑19 Patients

• Standard prophylactic dosing with either LMWH or UFH is recommended for non‑critically ill COVID‑19 inpatients. 6
• UFH 5,000 IU administered two to three times daily is an acceptable option for those with renal dysfunction. 6

Contraindications

• Absolute contraindication: Prior heparin‑induced thrombocytopenia (HIT). 4
• Relative caution: Patients with low body weight may require dose adjustment. 1

Mechanical Prophylaxis

• Mechanical methods (graduated compression stockings or intermittent pneumatic compression) should not be used as sole therapy unless pharmacologic prophylaxis is contraindicated. 2
• Combining mechanical and pharmacologic prophylaxis is advised for patients at high risk of VTE. 5

Efficacy Outcomes

• UFH prophylaxis reduces postoperative VTE incidence from 30.6 % to 13.6 % compared with no prophylaxis. 2

Cost Considerations

Unfractionated heparin is markedly less expensive than LMWHs and fondaparinux. 1

Unfractionated Heparin (UFH) for Thromboprophylaxis in Hospitalized Patients

Guideline Recommendations (American College of Chest Physicians)

• UFH is recommended as an effective thromboprophylactic option for hospitalized patients at increased risk of venous thromboembolism, and it is especially preferred in those with severe renal insufficiency. 7
• The ACCP strongly recommends low‑dose UFH for medically ill hospitalized patients with elevated thrombosis risk (Grade 1B). 7

Dosing Regimens

• Prophylactic dose: 5,000 IU UFH subcutaneously every 8 hours (three times daily) (Grade 1B). 7
• Alternative dose: 5,000 IU UFH subcutaneously every 12 hours (twice daily) (Grade 1B). 7

Specific Patient Populations

Critically Ill Patients

• For patients in intensive‑care units, the ACCP suggests using UFH or low‑molecular‑weight heparin for thromboprophylaxis (Grade 2C). 7

Patients with Active or High Bleeding Risk

• When active bleeding or a high risk of major bleeding is present, the ACCP advises against pharmacologic thromboprophylaxis (Grade 1B) and recommends mechanical methods such as graduated compression stockings or intermittent pneumatic compression (Grade 2C). 7

Duration of Prophylaxis

• UFH prophylaxis should be continued throughout the hospital stay until the patient regains full mobility and while risk factors (e.g., immobility, active cancer, recent surgery) persist.
• The ACCP recommends not extending prophylaxis beyond the period of acute immobilization or hospitalization (Grade 2B). 7